Saturday 17 October 2026
Export TLIS’s income statement to Excel — free account
Talis Biomedical Corporation
TLIS Healthcare Medical Devices
Talis Biomedical Corporation’s revenue for fiscal 2023 (year ended December 2023) was $2.1 million, down 55.7% from fiscal 2022. Operating cash flow growth for three consecutive years.
2.84
0.00
0.00%
Follow TLIS
| Older periods | Sep '23 | Dec '23 | Mar '24 | Jun '24 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | — |
P/S ratio |
4.84 | 6.85 | 15.66 | — | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | — | |
P/Operating CF |
(0.95) | (1.29) | (2.41) | — | |
P/B ratio |
0.13 | 0.21 | 0.27 | — | |
Price to Tangible BV |
0.13 | 0.21 | 0.27 | — | |
EV/Sales |
(35.23) | (29.11) | (55.46) | — | |
EV/EBITDA |
1.01 | 0.94 | 0.90 | — | |
EV/Operating CF |
1.40 | 1.17 | 1.27 | — | |
EV/FCF |
1.38 | 1.16 | 1.26 | — | |
Quick Ratio |
10.41 | 8.75 | 7.43 | 7.30 | |
Current Ratio |
10.60 | 8.86 | 7.51 | 7.76 | |
Net Debt/EBITDA |
5.25 | 5.39 | 5.08 | 6.31 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.01 | 0.02 | 0.01 | 0.00 | |
Operating CF/Net income |
0.71 | 0.84 | 0.49 | 1.28 | |
Capex/Depreciation |
(0.32) | 0.44 | 0.11 | 1.00 | |
Research and Development Expense of Revenue |
5,930.00% | 4,123.59% | 3,469.86% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
6,287.86% | 3,385.64% | 15,960.27% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
765.71% | 523.08% | 823.29% | 0.00% | |
Graham Net Nets |
6.01 | 3.57 | 2.93 | — | |
Graham Number |
0.00 | 0.00 | 0.00 | — | |
Earnings Yield |
(715.38%) | (425.06%) | (369.76%) | — | |
Free Cash Flow Yield |
(527.64%) | (367.67%) | (281.73%) | — | |
Revenue per Share |
0.08 | 0.11 | 0.04 | 0.00 | |
Operating CF per Share |
(6.13) | (6.25) | (3.53) | (6.22) | |
Capex per Share |
(0.04) | 0.05 | 0.02 | 0.05 | |
Free Cash Flow per Share |
(6.16) | (6.20) | (3.51) | (6.17) | |
Cash per Share |
48.37 | 42.22 | 38.60 | 32.85 | |
Shareholders Equity per Share |
44.83 | 38.03 | 31.11 | 26.68 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
44.83 | 38.03 | 31.11 | 26.68 | |
Free Cash Flow |
(11.21) | (11.26) | (6.40) | (11.25) | |
Working Capital |
81.08 | 68.91 | 61.70 | 55.41 | |
Capital Expenditures |
(0.07) | 0.09 | 0.03 | 0.08 | |
Net Current Asset Value |
63.86 | 52.13 | 45.36 | 39.53 | |
EV/EBIT |
0.96 | 0.93 | 0.89 | — | |
Capex to Sales |
0.50 | (0.48) | (0.41) | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | — | |
| Other line items | |||||
Average Receivables |
0.22 | 0.18 | 0.07 | — | |
Average Payables |
3.40 | 2.55 | 3.75 | 3.14 | |
Average Assets |
150.66 | 131.98 | 107.77 | 97.89 | |
Average Common Equity |
116.97 | 97.92 | 83.40 | 72.39 |
Columns are period end dates